Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-1353
- Development stage
- Preclinical
- Lead developer
- Septerna
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP-1353 is an orally available, potent, and selective small molecule agonist of the parathyroid hormone 1 receptor (PTH1R). Developed by Septerna, the compound is designed to mimic the action of parathyroid hormone (PTH) to regulate calcium and phosphate homeostasis. In preclinical models of hypoparathyroidism, such as thyroparathyroidectomized (TPTx) rats, oral administration of SP-1353 demonstrated sustained control of serum calcium and phosphate levels within the therapeutic range, as well as modulation of key bone turnover biomarkers. SP-1353 represents a potential oral alternative to injectable PTH peptide therapies for the treatment of hypoparathyroidism and other PTH-related disorders.
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on SP-1353.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-1353.